Skip to content
Pages
Posts by category
- Category: Events
- Category: News
- Category: Uncategorized
Resources
- Discovery, Characterization, and Manufacture of Peptide Radiopharmaceuticals
- Orthotopic and Metastasis Tumor Models in Rats
- Syngeneic Tumor Models with Resistance Mechanisms to PD-1 Blockade
- Armoring CAR-T Therapy with PD-1 Blockade
- Heme Oxygenase-1-Targeting Molecules
- DEL-Generated Endocytosis Receptor-Binding Peptides for Oligonucleotide Delivery
- Antibody Discovery Platform
- OncoWuXi Express: PSMA Overexpressing PC3 Tumor Model
- AACR 2024 Posters: Sneak Peek
- PROTAC Optimization Strategies
- T-DXd Resistant Tumor Models with ABCG2
- OncoWuXi Express: Adenovirus Vaccine AD5-HPV Inhibits Tumor Growth by Stimulating Immunity
- Rare Disease Therapeutics: Accelerating Development and Improving Access
- Addition of Covalent Warhead and DEL-Generated Hit Fragmentation Empower FBDD
- Establishment of EGFR TKI-Resistant Tumor Models
- iMN041: Prodrug with a Unique Antitumor Immune Response
- DNA-Compatible Cyclizations
- EML4-ALK Cell Lines and In Vivo Models
- High-Dimensional Flow Cytometry Platform
- STX-478, a Mutant-Selective, Allosteric PI3Kα Inhibitor Spares Metabolic Dysfunction and Improves Therapeutic Response in PI3Kα-Mutant Xenografts
- How to Accelerate the Synthesis of PROTACs: Strategies and Case Studies
- OncoWuXi Express: FaDu ATM Knockout Tumor model
- DEL Insight: Novel Applications with the Bifunctional Linker of DNA-encoded Molecules
- Cryo-EM
- High Throughput Protein Production
- Immune-Avatar Humanized Tumor Models
- Expanded Applications of PDX Models
- Emerging Drug Discovery Strategies for Targeted Protein Degradation
- Leveraging Animal Models to Combat Drug Resistance in Cancer Therapy
- TAAR1 as an Emerging Target for the Treatment of Psychiatric Disorders
- One Stop Target-to-Hit Platform: STATs
- OncoWuXi Express: Review of SITC 2023 Annual Meeting
- Preclinical platform for nucleic acid drug evaluation: siRNA and mRNA therapeutics
- Baricitinib treatment reduces the expansion of CD8+ T cells in C3H mice with skin grafts-induced alopecia areata
- Administration of JAK and TYK2 inhibitors successfully ameliorate the severity of T cell transfer-induced colitis in mice
- Upregulation of drug metabolism enzymes mediates ADC resistance in a HER2-positive cancer cell line
- Covalent Fragment-based Drug Discovery: BTK Inhibitors
- Novel Approaches to Targeted Protein Degradation
- One Stop Target-to-Hit Platform: Helicases
- Pioneering Advanced Modalities in Early Drug Discovery
- One Stop Target-to-Hit Platform: CDKs and CDK-Cyclin Complexes
- Colitis-Associated Cancer Mouse Model
- In Vivo Models of Tumor Complications
- Fibrosis Models in Mice and Rats
- OncoWuXi Express: In Vitro Hydrogel-based 3D Tumor Models
- GPCR-Membrane Protein Platform
- Advances and Biological Evaluation of Oligonucleotide Drugs
- Biophysical and Structural Biology Methods Enable Fragment-Based Ligand Discovery
- AAV Gene Therapy: Discovery and Optimization
- Parallel Purification of High-Quality Therapeutic Targets
- Negative Allosteric Modulation of the µ-Opioid Receptor
- Combined Inhibition of KRAS G12C and PD1 Boosts Therapeutic Efficacy via Conditioning of Tumor Microenvironment
- Progress and Challenges in Tumor Vaccine Development
- Discovery and Characterization of ZL-2201, a Potent, Highly Selective, and Orally Bioavailable Small-molecule DNA-PK Inhibitor
- Osimertinib-Resistant Cell Lines and Models
- Empowering Small Molecule Drug Discovery by Automatic DEL Screening
- Control of the Antitumor Activity and Specificity of CAR T Cells via Organic Adapters Covalently Tethering the CAR to Tumor Cells
- OncoWuXi Express: Large-scale Cell Panel Screening Platform for Integrated Pharmacogenomics and Bioinformatics Research
- Structure-Based Design and Synthesis of Potent and Selective KRAS G12D Inhibitors
- Anti-Tumor Nucleic Acid Drug Discovery Platform
- Enhertu-Induced Resistant Tumor Models
- Dianthus Platform: Screening for Modulators of SIK3
- Dianthus Platform: Screening for CRBN-DDB1 Proteolysis-Targeting Chimeras and Molecular Glues
- Dianthus Platform: Screening for Inhibitors of PIK3CA-PIK3R1
- Dianthus Platform: Screening for Inhibitors of PRMT5-WDR77
- Dianthus Platform: Screening for Modulators of STING
- Oncology Cell Panel Screening Platform
- Discovery of CVN636: A Highly Potent, Selective, and CNS Penetrant mGluR7 Allosteric Agonist
- OncoWuXi Express: In vitro and in vivo evaluation of an mRNA-encoded bispecific antibody (EpCAM/CD3)
- Structural Biology Platform Facilitates Discovery of Glutathione S-Transferase Inhibitors, Offering Novel Pathways for Drug Development
- Recent Advances in Peptide Drug Discovery
- Screening Methods to Identify RNA-Targeting Small Molecules
- Atopic Dermatitis Models
- Metastasis-Related In Vitro Assays and Xenograft Models
- Jurkat Reporter Cell Lines for Immunotherapy Drug Screening
- Discovery of Novel GST Inhibitors Identified from a DNA-Encoded Library
- Discovery and Characterization of Proteolysis Targeting Chimeras: Tissue Transglutaminase
- Translational Pharmacology of CNS and Metabolic Disorders for Testing New Modality Therapies
- One Stop Target-to-Hit Platform: PIK3CA–PIK3R1
- One Stop Target-to-Hit Platform: Protein arginine methyltransferase 5 (PRMT5)
- One Stop Target-to-Hit Platform: Cyclin-dependent kinase 2 (CDK2)
- One Stop Target-to-Hit Platform: Werner Syndrome Helicase (WRN)
- Emerging Modalities in Drug Discovery
- Oligonucleotide Therapeutics: Drug Discovery Through Tightly Coupled Chemistry and Biology
- DELvision: Improving Data-Driven Drug Discovery
- Alopecia Mouse Models
- New study by Promega and WuXi AppTec demonstrates novel chemical probes from DELs
- Oncolytic Virus Platform
- Case Study: Clinically Relevant NASH Animal Model
- Discovery and preclinical profile of LX-039, a novel indole-based oral selective estrogen receptor degrader (SERD)
- DELs enable the development of BRET probes for target engagement studies in cells
- In Vitro Immunology Assay Platform
- Evaluation Platform for Bispecific Antibodies
- Lysosomal Storage Disease Mouse Models
- CD34+ Hematopoietic Stem Cell Differentiation Platform
- Inhibition of the hERG potassium ion channel by non-nucleoside CMV polymerase antiviral inhibitors
- TEAD Proteins Associate With DNA Repair Proteins to Facilitate Cellular Recovery
- AACR 2023: Comparison of two DTH models for T cell-mediated immunity
- Enzalutamide-resistant LNCaP ARF877L Mutation KI model
- Recent Advances in Library Synthesis to Accelerate Medicinal Chemistry Research
- Gout Models
- Drug Resistant Models
- Cancer Pharmacology Services
- Large Animal Disease Models
- Autoimmune and Inflammatory Disease Models
- Immune Profiling Platform
- Tumor Cell Panel | Screening Services
- Clinical Biomarkers
- Single-cell RNA Sequencing Services
- Research Chemistry Services
- Rare Genetic Disease Platform
- Immunology Assays
- Inflammatory Bowel Disease Models
- Regenerable Surface Plasmon Resonance (SPR) Surfaces for Reliable, Cost-Effective, and Wide-Ranging Applications
- DNA-Encoded Macrocyclic Peptide Libraries Enable the Discovery of a Neutral MDM2–p53 Inhibitor
- Discovery of RNA Targeting Small Molecules - Our Toolbox for RNA Drug Discovery
- Biophysical and Structural Biology Methods Enable Fragment-based Covalent Ligand Discovery of Human BTK
- DNA-Encoded Libraries for the Discovery of Small-Molecule Hits
- DNA-Encoded Libraries: DELight Handbook
- DNA-Encoded Libraries: DELight User Manual
- DNA-Encoded Libraries: DELight Flyer
- PRMT5-WDR77 Services Platform
- PIK3alpha Services Platform
- Orthotopic and Metastasis Syngeneic Models
- DLL3-Related PDX Models
- c-MET Related In Vivo Models
- Discovery of Potent and Selective Dual Leucine Zipper Kinase/Leucine Zipper-Bearing Kinase Inhibitors
- Case Study: DEL Data Combined with In Silico Deep-Learning Model
- NLRP3 Services Platform
- KRAS Services Platform
- DNA-Encoded Libraries: DELopen Handbook
- DNA-Encoded Libraries: DELopen User Manual
- DNA Encoded Libraries: DELopen Flyer
- XPRESS Portfolio: Off-the-Shelf Crystallography
- Computer-Aided Drug Discovery Services
- DDC 2023: Biophysical & Functional Characterization of Bifunctional Small Molecules Enables TPD Drug Discovery
- AACR 2023: Integrated platform enables KRAS-targeted drugs discovery
- AACR 2023: Therapeutic potential of polatuzumab vedotin for the treatment of diffuse large B-cell lymphoma
- AACR 2023: A tailored platform enables BRAF-targeted drug discovery and precision medicine
- Ready-to-Go Biophysical Assays
- Cutting-Edge Crystallography Services
- Crystal-Grade Protein Production
- Discovery Newsletter: April 2023
- Discovery and preclinical evaluations of GST-HG131, a novel HBV antigen inhibitor for the treatment of chronic hepatitis B infection
- Development of Highly Potent Noncovalent Inhibitors of SARS-CoV-2 3CLpro
- BRAF-Related In Vivo Models
- Alpha‐kinase 1 (ALPK1) agonist DF‐006 demonstrates potent efficacy in mouse and primary human hepatocyte models of hepatitis B
- Xenograft and Syngeneic Tumor Models in Rats
- Optimization and Mechanistic Investigations of Novel Allosteric Activators of PKG1α
- Large-scale synthesis of a Notum inhibitor employing a modified Sakai reaction as the key step
- Discovery and Structural Characterization of Small Molecule Binders of the Human CTLH E3 Ligase Subunit GID4
- Fluoroalkane modified cationic polymers for personalized mRNA cancer vaccines
- KRAS-related Genetically Engineered Cell Lines and In Vivo Models
- WuXi Biology Fact Sheet
- Targeted Protein Degradation
- In Vitro Imaging Services
- CDK4/6 Inhibitor Resistant Breast Cancer Models
- Ligand Finding and Chemistry Workflows for Targeted Protein Degradation
- Biological Characterization and Development Workflows for Targeted Protein Degradation
- OncoWuXi Newsletter December 2022
- Discovery Newsletter Special New Year Edition 2023
- DNA-encoded chemical libraries
- Introduction into Fragment Based Drug Discovery
- Drugging the Undruggable: Leveraging the Right Screening Methods for Challenging Targets
- WuXi AppTec in vitro Neuroscience Services
- OncoWuXi Newsletter November 2022
- Discovery Newsletter November 2022
- How Does It Work? | Protein Based Vaccines
- How Does It Work? | Adenovirus Vaccines
- How Does It Work? | mRNA Vaccines
- How Does It Work? | Peptide-Oligonucleotide Conjugates
- How Does It Work? | Aptamers
- How Does It Work? | Individualized Oligonucleotide Therapies
- How Does It Work? | Antibody Drug Conjugates
- How Does It Work? | Antisense Oligonucleotide Therapy
- How Does It Work? | Peptibodies
- PD-1 Blockade Protein in 4th Generation Armored CAR-T Cells Enhances Cytotoxicity Effect with in vitro Re-challenge System
- Engineered Oncolytic Viruses Expressing Immunomodulatory Genes Enhances In Vitro Anti-Tumor Cellular Immune Responses
- WuXi AppTec Oligonucleotide Biology Platform
- How Does It Work? | Targeted Protein Degrader
- How Does It Work? | RNAi
- Oligonucleotide Drug Development (CMC)
- Oligonucleotide Drug Discovery
- Pain Discovery Assays & In Vivo Models
- OncoWuXi Newsletter: June 2022
- WuXi AppTec Discovery Services
- Bone metastasis platform to evaluate prophylaxis and treatment
- Quality Control for DNA-Encoded One-Bead-One-Compound (OBOC) Libraries
- Discovery of RNA Targeting Small Molecule Using DNA-Encoded Library Technology
- Integrating Practical Machine Learning and Quantum Mechanics Tools to Synthesis in Medicinal Chemistry
- Structure-based optimization of hydroxylactam as potent, cell-active inhibitors of lactate dehydrogenase
- Drug Discovery: Screening Approaches for Rapid Assessment of Target Tractability
- HIJACKING CELLULAR MECHANISMS TO TREAT COMPLEX DISEASES
- RARE DISEASES: OPPORTUNITIES AND CHALLENGES FOR TREATMENTS DELIVERED BY ADENO-ASSOCIATED VIRUSES
- Optimizing Drug Pipelines With Biophysical Methods
- Brain metastasis mouse models for the evaluation of multikinase inhibitors on ROS1-fusion-positive lung cancer
- Intra-carotid artery brain metastasis models for the evaluation of lung and breast cancer drugs
- Developing drug-induced resistant tumor models for efficacy evaluation of next-generation anticancer therapies
- Developing a panel of orthotopic syngeneic tumor models for IO drug discovery
- Development of an integrated in vitro and in vivo OVA-specific system for cancer vaccine discovery
- Mouse hind limb tumor metastatic model to evaluate prophylaxis and treatment
- Evaluating cancer therapies combining radiotherapy with immunotherapy or inhibitors of the DNA damage response
- Meeting Neurodegenerative Disease Head-On with Emerging Drug Discovery Strategies
- Evaluation of the efficacy of ADC in vitro and in vivo
- Structure determination: comparison of methods
- WuXi Discovery Services Newsletter: November 2021
- WuXi Discovery Services Newsletter: October 2021
- WuXi Discovery Services Newsletter: June 2021
- WuXi Discovery Services Newsletter: April 2021
- WuXi Discovery Services Newsletter: March 2021
- WuXi Discovery Services Newsletter: February 2021
- WuXi Biology GPCR Cell Lines and Assays
- Early in vitro safety panel - Assays and Data Summary
- One-Stop Target-to-Hit Solutions
- DELpro: A New Method of Hit Discovery
- Self Service DNA Encoded Library Screening
- Target to Hit Finding: New Methods in Fragment-Based Drug Discovery
- How to Accelerate the Rate Limiting Step in Drug Discovery, Synthesis of Target Molecules
- DNA-Encoded Libraries in Drug Discovery - Advances in Screening and Chemistry
- Enable Pharma and Biotech Innovation through Open-Access Platform
- Fragment Screening and Biophysical Hit Validation at WuXi AppTec’s HitS
- Immuno-Oncology Platform to Enable Discovery from Target to Drug
- Enabling Technologies for Targeted Protein Degradation Webinar
- NASH Animal Models and their Clinical Relevance – Quantitative Histopathology of Hepatic Fibrosis
- Introduction to Self-Service DNA-Encoded libraries (DELs)
- New Platform from Target-to-Hit
- Enable Pharma and Biotech Innovation through an Open-access Platform
- Enabling Technologies For Bifunctional Molecule Discovery And Characterization
- Cancer Immunotherapy and the Application of In Vitro Immunoassays in Drug Development
- Novel Peptide Hit Identification and Lead Generating Strategies for Drug Discovery
- Recent Advances in Library Synthesis to Accelerate Medicinal Chemistry Research
- Enabling Drug Discovery with Diverse Lead Generation Platforms
- Optimizing Drug Discovery Pipelines with Biophysical Methods
- Discovery of RNA binding molecule using DNA-encoded library technology
- Novel Strategies to Accelerate Discovery of Translatable Therapeutic Targets
- Quantitative Histopathology of Fibrosis in an Animal Model of NASH
- Aug 2021: Wuxi AppTec immune profiling in drug discovery and CLDN18.2-related tumor models.
- Validation of GVHD in mouse model for preclinical efficacy screen
- Engineered cell line panel complemented with in vivo models to enable next-generation target therapy discovery in cancer
- Establishment of drug induced resistant tumor models enable the development of next generation anticancer therapeutics
- Empowering Organic Syntheses with Quantum Mechanics Analyses
- The Synthesis of an Entrepreneur: Merging a Passion for Biochemistry, Synthetic Chemistry, and Bioactive Molecules in Academia
- Drug Hunter: Discovering New Frontiers in Cancer Treatments & Beyond
- Faster with high-speed fragment screening — Accelerate your drug discovery campaign
- Unlocking the potential of DEL | Inspire Hit Discovery
- Enabling Technology for Targeted Protein Degradation
- Establishment of KRAS-G12C inhibitor induced resistant tumor models enable the development of new generation KRAS-G12C inhibitors and combinatorial strategies
- Bifunctional Molecules: A Diverse New Modality That Unlocks New Target Classes
- How Diversity In Therapeutic Strategies Is Expanding The Drug Discovery Toolbox
- Outsourcing Drug Discovery and Development: Considerations For Emerging Biopharma Companies
- Quantum Mechanics for Organic Chemists: An Experimentalist Approach
- Antibody and Protein Preparation Services
- One-stop DEL services from target to hit series - DELpro
- Open Access to DEL for data sharing - DELopen
- DNA-encoded libraries for academic - DELopen Handbook
- DEL Screening - DELight Handbook
- Discovery Chemistry Outsourcing Services
- Translational Oncology
- Patient-Derived Xenograft (PDX) Tumor Models
- Immuno-Oncology Services
- Cell Line-Derived Xenograft (CDX) Tumor Models
- WuXi Oncology and Immuno-Oncology Services
- Virology and Viral Vector Platforms
- WuXi AppTec in vitro Safety Pharmacology Profiling
- in vitro Toxicity Services
- Hepatocellular Carcinoma (HCC) Models
- HBV Discovery Services
- Clinical Virology
- Establishment and Optimization of scRNA-seq assay to find the mechanism of immune therapy against tumors
- Identification of Tofacitinib, Filgotinib and Ruxolitinib on experimental Sjögren's syndrome model in mice
Resource Type
Resource Topics
